Design and formulation of Triamcinolone chewing gum for treatment of aphthous ulcers

Abstract

Aphthous stomatitis is a common disease characterized by frequent formation of non-contagious oral ulcers. Triamcinolone can be used for its symptomatic treatment, and it seems that the formulation of triamcinolone gum can increase its therapeutic efficiency due to its many advantages.Aim: The design and formulation of triamcinolone medicated chewing gum for the treatment of aphthous is to relieve pain and reduce the frequency of wounds, and in this regard, determining the average healing time and the diameter of the lesion in millimeters were the parameters that were considered for this comparison. Method: First, the calibration curve for triamcinolone was drawn. After making triamcinolone medicated gum, evaluation tests such as content uniformity, friability, hardness and dissolution were performed. In order to draw the release profile by evoking chewing movements by the device, the gums were placed in a chamber with a temperature of 35 degrees Celsius. For the clinical trial, chewing gums containing medicine and placebo were given to two different groups among the volunteers suffering from oral aphthous and the results were analyzed. Results and Discussion: According to the release test data, 91% of the drug is released from the formulated gum within 1.5 hours. Compared to the control group, the time to stop the pain of the lesions decreases with the use of medicated gum containing triamcinolone. The rate and speed of drug release increased due to the use of glycerin in the formulation. In this study, medicated gum had more clinical efficacy than oral paste in the treatment of mouth ulcers. Conclusion: In this study, by using of triamcinolone medicated gum, the healing time and changes in the diameter of the lesion in patients showed a significant decrease compared to the gum without triamcinolone.